Disparities in clinical trial enrollment at a Canadian comprehensive cancer center: A 15‐year retrospective study

Abstract

IntroductionDisparities in clinical trials (CTs) enrollment perpetuate inequities in treatment access and outcomes, but there is a paucity of Canadian data. The objective of this study was to examine disparities in cancer CT enrollment at a large Canadian comprehensive cancer center.MethodsRetrospective study of CT enrollment among new patient consultations from 2006 to 2019, with follow‐up to 2021 (N = 154,880), with the primary outcome of enrollment as a binary variable. Factors associated with CT enrollment were evaluated using multivariable Bayesian hierarchical logistic regression with random effects for most responsible physician (MRP) and geography, adjusted for patient characteristics (sex, age, language, geography, and primary care provider [PCP]), area‐level marginalization (residential instability, material deprivation, dependency, and ethnic concentration), disease (cancer site and stage), and MRP (department, sex, language, and training). A sensitivity analysis of the cumulative incidence of enrollment was conducted to account for differences in disease type and follow‐up length.ResultsCT enrollment was 11.2% overall, with a 15‐year cumulative incidence of 18%. Lower odds of enrollment were observed in patients who were female (adjusted odds ratio [AOR], 0.82; 95% confidence interval [CI], 0.78–0.86), ≥65 years (AOR vs. <40, 0.61; 95% CI, 0.56–0.66), non‐English speakers (0.72; 95% CI, 0.67–0.77), living ≥250 km away (AOR vs. <15 km, 0.71; 95% CI, 0.62–0.80), and without a PCP. Disease characteristics accounted for the largest proportion of observed variation (20.8%), with significantly greater odds of enrollment in patients with genitourinary cancers and late‐stage disease.ConclusionSignificant sociodemographic disparities were observed, suggesting the need for targeted strategies to increase diversity in access to cancer CTs in Canada.